Efficacy and safety of T4020 versus its vehicle in patients with chronic neurotrophic keratitis or corneal ulcer.
RESEARCHER: Dr. Jesús Merayo Lloves FINALIZADO Efficacy and safety of T4020 versus its vehicle in patients with chronic neurotrophic keratitis or corneal ulcer. INDICATION: Patients with neurotrophic keratitis or neurotrophic corneal ulcer TREATMENT: Cacicol® PROMOTOR: Laboratoires THÉA
A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.
RESEARCHER: Dr. Jesús Merayo Lloves ACTIVO A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to […]
“Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye”
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO “Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye” INDICATION: Pacientes con ojo seco leve o moderado TREATMENT: AVX-012 PROMOTOR: Avizorex Pharma
Treatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye.
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz ACTIVO Treatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye. INDICATION: Patients with Macular Degeneration Associated with the Wet Age TREATMENT: Aflibercept PROMOTOR: Bayer AG
A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)
RESEARCHER: Prof. Luis Fernández-Vega Sanz RECLUTANDO A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD) INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda). TREATMENT: OPT-302 PROMOTOR: […]
Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC)
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz ACTIVO Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC) INDICATION: Patients with polypoid choroidal vasculopathy TREATMENT: Aflibercept PROMOTOR: AIBILI
Phase IV multicentre and single-group interventional study to evaluate a model for the treatment of and extension with intravitreal aflibercept for the treatment of secondary macular edema to the occlusion of the central retinal vein
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz RECLUTANDO
Double masked SYL1001 study in patients with moderate or severe dry eye disease
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO Double masked SYL1001 study in patients with moderate or severe dry eye disease INDICATION: Patients with moderate to severe dry eye TREATMENT: SYL1001 PROMOTOR: SYLENTIS